Press Release

News Archive

Japanese chemical firm Toray partners with QB3@953 to pursue breakthroughs in treatment of neurological diseases

Japanese chemical firm Toray partners with QB3@953 to pursue breakthroughs in treatment of neurological diseases San Francisco, CA, May 11, 2017 – QB3@953, the Bay Area’s premier life science incubator, welcomes Japan’s chemical giant Toray as its newest partner. The arrangement offers Toray the opportunity to nurture its budding pharmaceutical enterprise while bringing new expertise and trans-Pacific relationships to QB3@953’s […]

Read more

AMGEN and QB3@953 announce winners of the AMGEN GOLDEN TICKET

AMGEN AND QB3@953 ANNOUNCE WINNERS OF THE AMGEN GOLDEN TICKET San Francisco, CA, June 11, 2017 – Two Diagnostic Companies Will Receive Lab Space and Other Benefits at San Francisco Life Sciences Incubator Amgen (NASDAQ: AMGN) and QB3@953 today announced that Darmiyan and Enable Biosciences have won the Amgen Golden Ticket at QB3@953. Each company receives one year of lab […]

Read more

QB3@953 Companies Attract $1.36B In Capital

QB3@953 Companies Attract $1.36B In Capital San Francisco, CA, May 1, 2017 – QB3@953 proved definitively that its incubator facilities allow life science startups to progress at lightening speed, making a huge impact on the life-science ecosystem of the Bay Area. QB3@953 tenant and alumni companies are thriving. In the three short years since its founding, QB3@953 companies attracted $1.36Bn […]

Read more

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company Telo Therapeutics enters into an Oncology-focused research collaboration with GSK San Francisco, CA, Feb 2, 2017 – QB3@953, the Bay Area’s premier life science incubator, today announced the collaboration between one of its member companies, Telo Therapeutics, and one of its sponsor companies, GlaxoSmithKline (GSK). Telo Therapeutics […]

Read more

Perlara PBC Announces Pharma Collaboration with Novartis

Perlara PBC Announces Pharma Collaboration with Novartis SAN FRANCISCO, Oct. 19, 2016 /PRNewswire/ Perlara PBC (previously Perlstein Lab PBC) today announced the formation of a drug discovery and development collaboration with Novartis to identify new definitive therapeutics for lysosomal storage disorders, starting with lead program Niemann-Pick Type C Disease. In addition to the collaboration, Novartis has made an equity investment […]

Read more

Amgen Incubators Grow Startup for Harvest

Amgen Incubators Grow Startup for Harvest Venture division seeks access to technology, potential takeovers. San Fernando Valley Business Journal, July 11-24, 2016 By STEPHANIE HENKEL, Staff Reporter Amgen inc. hopes to get in on more ground floors by sponsoring startups in the biotech hubs in Cambridge, Mass. and, more recently, in San Francisco. The Thousand Oaks biopharmaceutical company last month […]

Read more

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies Kite to License Cell Design Labs’ Synthetic Biology Technology for Applications in Acute Myeloid Leukemia with Exclusive Option for Applications in B-cell Malignancies Cell Design Labs’ Reversible ‘On/Off Switch’ Technology Provides Dynamic Range of Control to Precisely Regulate Activity of Engineered CAR […]

Read more

Cell Design Labs Executes Series of Private Financings

Cell Design Labs Executes Series of Private Financings New Company Focused on Discovering and Developing Next-Generation Immunotherapies for Cancer and Other Complex Diseases   SAN FRANCISCO, Calif. June 2, 2016 — Cell Design Labs, Inc. today announced it has executed a staged series of investor and strategic partner financings totaling $34.4 million to fund the company’s start-up operations. The investors, […]

Read more

Alector Announces $29.5M Series D Financing

Alector Announces $29.5M Series D Financing Alector LLC, a biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, today announced that it has raised $29.5 million in a Series D financing. After having completed a Series C financing of $32 million earlier in the year, this financing brings the total amount […]

Read more

4D Molecular Therapeutics Announces Collaboration With Pfizer, Inc.

4D Molecular Therapeutics Announces Collaboration With Pfizer Inc. for Cardiac Gene Therapy Vector Discovery and Development 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced both an investment by and a collaboration and license agreement with Pfizer Inc. to discover and develop targeted and proprietary next-generation AAV vectors for cardiac disease […]

Read more
Page 1 of 212

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter